Drug maker Alexion, developer of the rare disease drug eculizumab (Soliris), announced Friday that the FDA has accepted for priority review its long-acting C5 complement inhibitor, ravulizumab (Ultomiris), which offers less frequent administration than eculizumab.
Drug maker Alexion, developer of the rare disease drug eculizumab (Soliris), announced Friday that the FDA has accepted for priority review its long-acting C5 complement inhibitor, ravulizumab (Ultomiris), which offers less frequent administration than eculizumab. The FDA will review ravulizumab for the treatment of atypical hemolytic uremic syndrome (aHUS), a progressive disease that can lead to irreversible organ damage and premature death.
Alexion expects a regulatory decision by October 2019.
“This acceptance is an important step in our efforts to deliver a potential new standard of care to people living with this devastating disease,” said John Orloff, MD, executive vice president and head of research and development at Alexion. “We look forward to working closely with the FDA to facilitate a rapid review of this application.”
Earlier this year, Alexion announced that its study in 56 patients with aHUS had met its primary end point; in the first 26 weeks of treatment, 53.6% of patients (95% CI, 39.6%-67.5%) demonstrated a complete thrombotic microangiopathy response, defined by hematologic normalization and improved kidney function for at least 28 consecutive days.
Ravulizumab, which is administered every 8 weeks versus every 2 weeks for eculizumab, has already gained approval for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), and Alexion is studying the drug in patient with myasthenia gravis (MG).
Alexion noted in its fourth quarter 2018 earnings call that it hopes to transition patients already receiving the older eculizumab (which carries indications in aHUS, PNH, and MG) onto the newer ravulizumab in the near future. Alexion’s chief commercial officer, Bryan Goff, said that the company is hoping for a 70% conversion from eculizumab to ravulizumab within the next 2 years ahead of biosimilar market entry.
Meanwhile, biosimilars of eculizumab are advancing; last week, drug maker Amgen reported data demonstrating pharmacokinetic and pharmacodynamic equivalence of its proposed biosimilar (ABP 959) and the reference eculizumab, and the biosimilar developer is currently recruiting for its phase 3 clinical trial of the biosimilar in PNH.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.